Labiotech.eu

News and Trends 24 Mar 2017

Novartis puts the Development of two Anti-Aging Drugs in American Hands

PureTech will take on the development of two mTORC1 inhibitors from Novartis aimed at stopping the decline of the immune system associated with age. Novartis is building up the portfolio of PureTech, a Boston-based healthcare company listed on the London stock market. Originally an investment firm, it now has put together a drug pipeline from […]

March 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Infant Bacterial Therapeutics Biotech of the Week

Startup Scout 24 Mar 2017

This Swedish Biotech Uses Bacteria to Treat Diseases in Infants

This week’s biotech brought us to Scandinavia. Based in Sweden’s capital, Stockholm, Infant Bacterial Therapeutics aims to treat rare diseases affecting newborns by targeting the infant microbiome. Mission: Infant Bacterial Therapeutics (IBT) aims to treat rare diseases affecting infants for which there is currently no treatment available. The company makes use of live bacterial therapeutics, which modulate inflammatory […]

March 24, 2017 - 2 minutesmins - By Melanie De Almeida

Research Biosensor Chip Bacterial Infections 1

News and Trends 24 Mar 2017

New Biochips Quickly Identify the Best Antibiotic for each Bacterial Infection

Scientists from Israel have piloted a new silicon biosensor chip that can rapidly identify the best antibiotics for treating a bacterial infection. Antibiotic resistance makes up one of the major health challenges of the 21st century. Some of the major causes of the increasing numbers of resistant bacterial strains are overuse of antibiotics and mistreatment of infections. […]

March 24, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 23 Mar 2017

A Cheaper Heat-Stable Vaccine Could Prevent Child Deaths in Africa

An innovative rotavirus vaccine, BRV-PV, which does not require refrigeration, has passed Phase III trials in children living in sub-Saharan Africa. The Research and Epidemiology branch of the humanitarian organization Doctors without Borders (MSF), Epicentre, has published the results of its recent Phase III trial for a new oral vaccine against rotavirus infection. The vaccine, […]

March 23, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 23 Mar 2017

Galapagos Enters Clinical Trials with New Cystic Fibrosis Drug

Galapagos has announced to kick off a Phase I trial with its novel Cystic Fibrosis potentiator GLPG3067, triggering a €7M milestone payment from AbbVie. Galapagos and AbbVie teamed up in 2013, with the aim of developing a triple combination therapy for the treatment of Cystic Fibrosis (CF). Now, Galapagos announced the start of a Phase […]

March 23, 2017 - 2 minutesmins - By Melanie De Almeida

Interview 23 Mar 2017

Meet the CEO of this Intrepid Spanish Biotech exploring Epigenetics

Located right here in Barcelona, Oryzon is one of the world’s few epigenetics biotechs. I sat down with CEO Carlos Buesa to talk about its approach. Since its foundation in 2000, Oryzon has gone on to become the leader in epigenetic medicine and focuses on oncology. Most recently, the company announced the success of its lead […]

March 23, 2017 - 2 minutesmins - By Evelyn Warner

eppendorf bioflo120 sponsored e1490947196269

News and Trends 23 Mar 2017

Speed up R&D? Eppendorf is Offering a new Solution!

With their latest bioreactor system, BioFlo 120, Eppendorf is aiming to make bioprocesses more flexible and straightforward. Apart from brewing beer, bioprocesses play a major role in the biotech industry. Ever since the breakthrough of genetic engineering technologies in the end of the last century, we have started to exploit microorganisms or mammalian cells as […]

March 23, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 22 Mar 2017

Swedish Oncology Biotech Teams up with World Leading Cancer Center

The Swedish biotech Aprea Therapeutics has entered a new collaboration with the Memorial Sloan Kettering Cancer Center to study the effects of its lead APR-246. Based in Stockholm, Aprea therapeutics is focusing on the development of its only drug candidate, APR-246. The molecule targets the key tumor supressor p53 to restore its function. Now, in collaboration […]

March 22, 2017 - 2 minutesmins - By Melanie De Almeida

Pierre Fabre H Immune research collaboration 3

News and Trends 22 Mar 2017

France’s 2nd Biggest Pharma Enters New Partnership for Immunotherapies

With its new Fund for Innovation, Pierre Fabre will collaborate with H-Immune to use its ‘In Vitro Immunization’ (IVI) platform for the development of fully human monoclonal antibodies (mAbs). Pierre Fabre is the 2nd largest private pharmaceutical company in France and has recently made efforts to open up its innovation process. Since the establishment of the Pierre […]

March 22, 2017 - 2 minutesmins - By Melanie De Almeida

Interview 22 Mar 2017

Watch a Partner at Spain’s Largest VC talk Investment Strategy

At BIO Europe Spring, we met Karen Wagner, a General Partner at Ysios, the VC dominating Spain’s investment scene. She told us what’s on the firm’s radar. Spain’s largest VC has positioned itself in Barcelona, having identified the city’s potential to be the next biotech hub in Europe. It has funded key biotechs in Spain, including Sanifit, which claimed the […]

March 22, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 22 Mar 2017

What’s the Gold Standard for Therapeutic Antibodies?

Are fully human antibodies the new gold standard in therapeutic innovation? If you want to upgrade, here’s where to find them. If you’re curious about the future of antibody development, look no further than Humira. This monoclonal antibody (mAb) for various inflammatory diseases soared to become the best-selling biological in 2016. Humira is a fully human […]

March 22, 2017 - 4 minutesmins - By External Contributor

News and Trends 21 Mar 2017

A Potential First Treatment for a Rare Genetic Disease clears Phase I

Minoryx Therapeutics has successfully completed a Phase I trial for its lead compound MIN-102 targeting X-linked adrenoleukodystrophy (X-ALD). The Spanish biotech Minoryx is specialized on orphan diseases and its lead program is a PPAR-gamma agonist, MIN-102, which is in development for X-ALD. The company now announced the successful results of its Phase I trial with MIN-102 revealing the […]

March 21, 2017 - 2 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Novartis puts the Development of two Anti-Aging Drugs in American Hands

This Swedish Biotech Uses Bacteria to Treat Diseases in Infants

New Biochips Quickly Identify the Best Antibiotic for each Bacterial Infection

A Cheaper Heat-Stable Vaccine Could Prevent Child Deaths in Africa

Galapagos Enters Clinical Trials with New Cystic Fibrosis Drug

Meet the CEO of this Intrepid Spanish Biotech exploring Epigenetics

Speed up R&D? Eppendorf is Offering a new Solution!

Swedish Oncology Biotech Teams up with World Leading Cancer Center

France’s 2nd Biggest Pharma Enters New Partnership for Immunotherapies

Watch a Partner at Spain’s Largest VC talk Investment Strategy

What’s the Gold Standard for Therapeutic Antibodies?

A Potential First Treatment for a Rare Genetic Disease clears Phase I

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!